share_log

Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target

Benzinga ·  Apr 16 10:20

Wedbush analyst Laura Chico reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and maintains $48 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment